With Q1 reporting season now underway, Luisa & Kerry run through key highlights from Sanofi and Roche results with a focus on longer dosing interval Dupixent. As usual obesity is in focus after CMS had to extend its Medicare bridge program to allow patients access from July after payers failed to opt-in on time.